MBNL2

Across TCGA pan-cancer cohorts, MBNL2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MBNL2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where MBNL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MBNL2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

COAD, HNSC, and LSCC are the cancer types where MBNL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MBNL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	+0.852	<.001	10	view →
HNSC	All	III,IV	+0.278	<.001	7	view →
LSCC	Male	II,III,IV	−0.273	<.001	7	view →
PDAC	All	All	+0.547	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MBNL2–COAD

Open the COAD breakdown →